Margaret (Peggy) L Gulley
Professor of Pathology
Area of interest
Dr. Gulley is Director of Molecular Pathology in the Department of Pathology and Laboratory Medicine. She provides DNA and RNA-based laboratory services related to heritable disease, infectious disease, cancer, identity, and pharmacogenetics. Test results help in diagnosis, monitoring disease burden, screening high risk individuals, and predicting response to therapy. We welcome your ideas for new molecular tests to help our patients.
We investigate the contribution of Epstein-Barr virus (EBV) to the development of cancers including Hodgkin and non-Hodgkin lymphoma, nasopharyngeal carcinoma, and gastric cancer. We use molecular techniques to evaluate EBV gene expression and to localize viral products to particular cells in human tissue sections. Gene expression profiling allows us to characterize host/ viral interactions. Once validated as being useful, findings are translated to the clinical realm where they improve diagnosis and management of affected patients. For example, EBV viral load assays are used on a clinical basis to assist in diagnosis and monitoring of EBV-related malignancies. EBV encoded RNA (EBER) in situ hybridization is used to detect and localize EBV in paraffin embedded tissue or cytologic specimens. Immunohistochemistry and real-time rtPCR combined with microdissection localize viral gene products.
Unique Technical and Clinical Research Capabilities:
Clinical and research facilities are available for: DNA or RNA extraction and storage; Southern blot, real-time PCR or rtPCR, immunohistochemistry, karyotype, FISH, DNA sequencing, in situ hybridization, and microarrrays targeting a wide variety of clinically-relevant human gene products or infectious agents. For more information on our clinical, research and training programs, visit our website at: http://www.med.unc.edu/pathology/faculty/biosketch-of-dr-margaret-gulley
A document on "Validating Molecular Assays for Use in Clinical Trials" can be downloaded from our website,
Examples of EBV Assays available to other investigators:
Real Time PCR Assays:
APOB cellular gene normalizer
In Situ Hybridization Assays:
EBER RNA (with Oligo dT control)
Lytic EBV RNA (EA, with Oligo dT control)
Immunohistochemistry Detecting Latent EBV Infection:
LMP1 (CS1-4 clone)
LMP2 (4E11 clone)
Detecting Lytic EBV Infection:
BZLF1 (BZ.1 clone)
BMRF1 (G3-E31 clone)
RNA expression profiles of (latent and lytic) EBV gene products
DNA polymorphisms in the viral and host genomes
UNC has a wealth of clinical and basic scientists and epidemiologists cooperating to understand and better manage EBV-related neoplasia.
Awards and Honors
Dr. Gulley is active in the Association for Molecular Pathology (past president), the College of American Pathologists (CAP), and the Cancer Genome Atlas (TCGA) Project. She won the Lansky Award from the CAP Foundation and the Phil Blatt Award for Clinical Pathology Teaching at UNC.